Literature DB >> 2451265

Antiviral cytotoxic T lymphocyte induction and vaccination.

B T Rouse1, S Norley, S Martin.   

Abstract

In developing vaccines to counteract viral infections, it is important to produce reagents that engender the type of immune response best suited to provide protection and avoid immunopathology. Recovery from infection is the principal role of T cell immunity, and cells that recognize virus-infected cells (cytotoxic T lymphocytes) and kill them--often before new virus is replicated--represent a crucial component of the recovery process. The cytotoxic T lymphocytes are particularly important in situations where the load of infection is high. In this review the cells and mediators, as well as the viral and host cell antigens involved in antiviral induction of cytotoxic T lymphocytes, are discussed. Particular attention is paid to the importance of the intracellular pathway of processing taken by viral antigens and the outcome in terms of the recognition of cytotoxic T lymphocytes. The new types of vaccines--especially subunits, antiidiotypes, and recombinant viral vectors--are discussed in terms of their likely effectiveness at inducing cytotoxic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451265     DOI: 10.1093/clinids/10.1.16

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  27 in total

Review 1.  Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.

Authors:  A Tärnvik; M Eriksson; G Sandström; A Sjöstedt
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

2.  The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.

Authors:  P J Openshaw; K Anderson; G W Wertz; B A Askonas
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.

Authors:  A B Nesburn; S Slanina; R L Burke; H Ghiasi; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Timing of lymphocyte activation in neonates infected with human immunodeficiency virus.

Authors:  K Gallagher; M Gorre; N Harawa; M Dillon; D Wafer; E R Stiehm; Y Bryson; D Song; R Dickover; S Plaeger
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

5.  Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.

Authors:  M J Irwin; L S Laube; V Lee; M Austin; S Chada; C G Anderson; K Townsend; D J Jolly; J F Warner
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits.

Authors:  A B Nesburn; R L Burke; H Ghiasi; S Slanina; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Cell-mediated immune responses of lambs to challenge with bovine respiratory syncytial virus.

Authors:  A K Sharma; Z Woldehiwet
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

8.  Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay.

Authors:  T Vogel; S Norley; B Beer; R Kurth
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

9.  Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens.

Authors:  J C Bowen; S K Nair; R Reddy; B T Rouse
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

10.  Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein.

Authors:  M Shirai; T Akatsuka; C D Pendleton; R Houghten; C Wychowski; K Mihalik; S Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.